San Diego, Calif., March 10, 2016 – Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins announced today that academic co-founder, Professor Seth Cohen, Ph.D., will showcase the innovative metalloenzyme chemistry leadership through multiple presentations at the 251st American Chemical Society National Meeting taking place at the San Diego Convention Center from March 13-17, 2016.
“The number of presentations by Professor Seth Cohen and lab members clearly illustrate the depth and breadth of this transformational technology,” said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics. “We believe that metalloenzymes are an untapped class of potentially valuable drug targets, and with Dr. Cohen’s guidance, we look forward to advancing our drug discovery engine creating new first-in-class medicines for high unmet needs.”
Dr. Seth Cohen, Ph.D., co-founder of Forge Therapeutics and Professor in the Department of Chemistry and Biochemistry at the University of California, San Diego is presenting in a symposium in honor of the ACS Award for Distinguished Service in the Advancement of Inorganic Chemistry honoree. His talk is entitled ‘Designing metalloenzyme inhibitors to be invinceable” on Monday March 14th from 4:40pm to 5:10pm in Room 30C San Diego Convention Center.
Other presentations include:
- “Potent influenza endonuclease inhibitors development from metal-binding pharmacophore library screen” publication number 144
- “8-hydroxyquinoline as a scaffold for the development of New Delhi metallo-B-lactamase-1 inhibitors” publication number 146
- “Structural approach to elucidating metalloenzyme inhibitor selectivity” publication number 76
- “Synthesis and evaluation of libraries of metalloenzyme inhibitors” publication number 1173
- “Dipicolinic acid derivatives as inhibitors of New Delhi metallo-B-lactamase-1”publication number 334
- “Design and synthesis of Rpn11 inhibitors, prodrugs, and probe molecules” publication number 287
- “Studies on the selectivity of metalloprotein inhibitors and their effects on cellular metal ion homeostasis” publication number 292
- “Metal binding pharmacophores yields a potent inhibitor of the proteasome subunit Rpn11” publication number 308
To learn more about the ACS meeting please visit http://www.acs.org/content/acs/en/meetings/spring-2016.html
About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. (“Forge”) is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins. Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body. Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins. The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team). Forge Therapeutics, Inc., maintains its headquarters in San Diego, California. To learn more please visit www.ForgeTherapeutics.com